📰 Beckley Psytech News
Page 4 - Beckley Psytech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beckley Psytech. Real-time updates on events, politics, business and more.
January 4, 2024
Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo...
January 4, 2024
Psychedelic drug development firm atai Life Sciences (NASDAQ:ATAI) is investing $50 million in UK-based Beckley Psytech as part of a collaboration that...
December 16, 2023
Numinus Wellness Inc. announce that its research site, Cedar Clinical Research , has been chosen as one of multiple sites for Beckley Psytechs cutting-edge Phase 2b clinical trial for Treatment...
December 15, 2023
/PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative...
September 15, 2023
Start-ups are tweaking psychedelic compounds to treat mental health conditions.
September 14, 2023
Start-ups are tweaking psychedelic compounds to treat mental health conditions.
September 14, 2023
Start-ups are tweaking psychedelic compounds to treat mental health conditions.
June 3, 2023
Psychedelics startups want to transform mental healthcare. But first, they need to win over the skeptics and break the taboos.
May 4, 2023
BPL-003 is Beckley Psytech's patent-protected benzoate formulation of 5-MeO-DMT (also known as Mebufotenin) and is administered intranasally via an FDA-approved delivery device. The multi-centre